（来源：光明日报） 转自：光明日报 党旗飘扬映初心，医教协同启新程。2025年，三峡大学基础医学院（以下简称"学院"）始终以党建为引 领，将党的建设与学科建设、人才培养、科学研究等中心工作深度融合，在各领域精准发力、多点突 破，以高质量党建书写医学教育与科研服务新篇章。 党建铸魂 筑牢发展根基 学院以党建引领学科布局优化，聚焦大健康领域需求，推动"大健康与医药学科群"建设提质增效。2025 年，学院药理学与毒理学成功进入ESI前1%；成立医工交叉前沿技术研究所；成功举办三峡肿瘤防治高 峰论坛、第十三届全国生物治疗大会等多项国际会议。科研平台协同发力，学院依托1个省级、2个市 级、7个校级科研平台联动赋能，与多家医院、企业签订合作协议，形成党建引领下学科建设与科研创 新互促共进的良好格局。 文化育人 厚植医者情怀 学院深耕"博医"文化品牌，构建"党建+学风+服务"三维育人体系。"博医志愿红"服务队全年开展导医服 务、健康科普等活动50余场，累计服务时长超1000小时；"博医杯"系列赛事覆盖科研创新、临床技能等 领域，获中国国际大学生创新大赛省级金奖；深化"博医"学风与"一站式"学生社区品牌创建，将价值引 领贯穿 ...

"强叔不老，能饭能闯" "沧海何曾断地脉？白袍端合破天荒。"900多年前，苏轼贬居儋州时挥毫赋诗，写下海南文化教育史上 的名句。东坡或许不会想到，900多年后，一位院士在花甲之年南下海口，在医学教育领域大刀阔斧推 动改革——他拿起"手术刀"，为原本名不见经传的海南医科大学(原海南医学院)动真碰硬除沉疴，誓将 该校建成热带特色鲜明的国际化高水平医科大学，培养"能在热带阳光下把脉时代"的良医，为地方医学 院校改革闯出一条可复制的道路。 这位院士，就是肿瘤病理生理学家、上海交通大学医学院原院长陈国强。他以"强叔不老，能饭能闯"自 勉，出任校长后不到1年，海南医学院更名为海南医科大学，让空壳13年的海南省医学科学院变身实体 科研高地，新增9个硕博点；两年间，学校修订110余项校内规章制度，师生精神面貌焕然一新，教风学 风校风悄然改变，有组织科研稳步推进，附属医院改革如火如荼。 究竟是怎样的理念和行动成就了这样的改革？记者在海南自贸港全岛封关之际，走进了海南医科大学 (下文简称"海医")。 "要改就动真碰硬" "我为情怀、理想和自我完善而来，十年热血，愿倾天涯！唯有改变，方能'破天荒'……"2023年9月， 在上任3日 ...

Core Insights - Guangxi Medical University has announced six procurement intentions for laboratory instruments, with a total budget of 111 million yuan [2][3]. Procurement Overview - The procurement includes advanced instruments such as: - Coherent Raman Spectroscopy - Fully Automated Integrated Droplet Digital PCR - X-ray Powder Diffraction Instrument - Chemiluminescence Imaging System - Inductively Coupled Plasma Mass Spectrometry System - Rotational Shear Rheometer - Protein Liquid Chromatography System - The expected procurement date is December 2025 [3]. Instrument Descriptions - **Fully Automated Integrated Droplet Digital PCR**: This technology offers high sensitivity and absolute quantification of nucleic acids, crucial for applications in oncology, pathogen detection, and prenatal testing [4]. - **X-ray Powder Diffraction Instrument**: A fundamental tool for material characterization, it accurately determines crystal structures and compositions, essential for various fields including materials science and pharmaceuticals [5][6]. - **Rotational Shear Rheometer**: This instrument measures the flow characteristics and viscoelastic behavior of materials, applicable in polymer science, food science, and chemical engineering [7]. Research and Development Strengths - Guangxi Medical University is recognized as a leading medical institution in the region, with a strong focus on research in nasopharyngeal and liver cancers, contributing significantly to public health [11][13]. - The university has established several national-level research platforms, enhancing its capabilities in translational medicine and clinical applications [11][12].

Core Thesis - Afya Limited is viewed as a compelling investment opportunity due to its strong market position in Brazil's medical education sector, despite recent volatility in its stock price [2][5] Company Overview - Afya Limited operates as a medical education group in Brazil, having evolved from a single family-run medical school in 1999 to a leading provider through acquisitions and organic growth [2][3] - The company went public on Nasdaq in 2019 and has since raised capital to support its expansion [2] Market Position - Afya is the leading medical education provider in Brazil, benefiting from a regulated seat-authorization system that protects incumbents from oversupply [3] - Major shareholders, including Bertelsmann, purchased shares at $26.90 in 2022 and are currently experiencing a value dislocation, indicating potential upside for new investors [3] Financial Performance - Revenue and profitability have increased significantly, supported by strong cash generation and modest leverage, despite challenges such as aggressive mergers and acquisitions and currency depreciation [4] - The company has maintained a stable share count while capitalizing on favorable long-term demand fundamentals, with Brazil expected to nearly double its physician base over the next decade [4] Management and Strategy - The management team, led by CEO Virgilio Gibbon since 2016, has shown consistent execution through the IPO process, acquisitions, and operational scaling [4] - Afya's operations are characterized by a mix of regulated scarcity and proven management, positioning it as an attractive candidate for further investment [5]

Education & Humanitarian Impact - Gazan medical student's UK studies are described as 'life-changing' [1]

Core Insights - Afya Limited reported strong financial results for Q3 and the first nine months of 2025, reaffirming its full-year guidance and demonstrating significant growth in revenue and adjusted EBITDA margins [1][4][10]. Financial Performance - Q3 2025 revenue increased by 10.4% year-over-year to R$928.5 million, while revenue excluding acquisitions rose by 10.1% to R$926.2 million [4][25]. - For the nine-month period, revenue reached R$2,784.3 million, reflecting a 13.4% increase year-over-year, with revenue excluding acquisitions growing by 9.8% to R$2,696.7 million [4][25]. - Adjusted EBITDA for Q3 2025 was R$398.9 million, up 14.6% year-over-year, with an adjusted EBITDA margin of 43.0%, an increase of 160 basis points [4][28]. - For the nine-month period, adjusted EBITDA increased by 18.5% to R$1,291.7 million, with a margin of 46.4%, up 200 basis points [4][28]. Net Income and Earnings - Q3 2025 net income rose by 28.4% to R$159.4 million, while adjusted net income increased by 16.5% to R$192.7 million [4][32]. - For the nine-month period, net income reached R$593.0 million, a 19.9% increase, and adjusted net income was R$696.0 million, up 11.1% [4][32]. Cash Flow and Debt Management - As of September 30, 2025, cash and cash equivalents totaled R$996.8 million, a 9.4% increase from the previous year, with net debt reduced to R$1,342.2 million [4][36]. - The operating cash conversion ratio was 101.5%, with cash flow from operating activities increasing by 10.6% year-over-year to R$1,291.5 million [4][37]. Strategic Initiatives - The company has made significant advancements in its integrated ecosystem, focusing on enhancing educational services and medical practice solutions [5][10]. - Afya has launched AI-enabled enhancements to its platforms, supporting clinical productivity and decision-making [8]. - The company issued R$1.5 billion in commercial notes to strengthen its capital structure and repurchased shares from SoftBank, demonstrating a disciplined approach to capital management [9][41]. Segment Performance - The Undergraduate segment saw a 14.6% increase in revenue, driven by higher ticket prices and increased student enrollment [4][15]. - Continuing Education experienced growth in B2B revenue, while Medical Practice Solutions reported an increase in active payers, reflecting the value of its offerings [7][19].

Core Insights - Afya Limited, a leading medical education group and medical practice solutions provider in Brazil, has received authorization from the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education (MEC) to increase medical seats by 100 at ITPAC Porto Nacional [1] Company Summary - The increase in medical seats is specifically for ITPAC Porto Nacional – Instituto Tocantinense Presidente Antonio Carlos Porto S.A. (AFYA Faculdade de Ciências Médicas Bragança) [1]

Core Insights - Steven Madden reported quarterly earnings of $0.43 per share, missing the Zacks Consensus Estimate of $0.44 per share, and down from $0.91 per share a year ago, representing an earnings surprise of -2.27% [1] - The company posted revenues of $667.88 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 4.44%, compared to $624.67 million in the same quarter last year [2] - Steven Madden shares have declined approximately 22.8% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.27 on revenues of $690.07 million, and for the current fiscal year, it is $1.51 on revenues of $2.5 billion [7] - The estimate revisions trend for Steven Madden was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Shoes and Retail Apparel industry, to which Steven Madden belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Insights - Zunyi Medical University has announced four procurement intentions for laboratory equipment, with a total budget of 105 million yuan [1][2]. Procurement Overview - The procurement includes projects for research platform construction, teaching platform construction, experimental consumables, and reagents [2]. - The expected procurement period is from June to October 2025 [2]. Detailed Procurement List - Research Platform Construction Project: Budget of 49.99 million yuan, aimed at enhancing research capabilities [4]. - Teaching Platform Construction Project: Budget of 49.97 million yuan, focused on improving teaching facilities [4]. - Pharmaceutical Experimental Teaching Demonstration Center: Budget of 1.52 million yuan, intended to enhance experimental capabilities [4]. - Experimental Consumables and Reagents: Budget of 4 million yuan, aimed at meeting teaching and research needs [5]. Institutional Background - Zunyi Medical University is a key institution for medical education in China, with a strong emphasis on interdisciplinary research in biology, chemistry, environment, and materials [5]. - The university has established several high-level research platforms, including key laboratories in pharmacology and oncology, contributing significantly to regional economic and social development [6].

Core Insights - The event is the fifth edition of Afya Day, focusing on the company's commitment to physicians and showcasing its innovations and products [1][2] - The agenda includes presentations from various business units and discussions on trends in the medical career, emphasizing the company's physician-centric approach [2][3] - The introduction of the new Medical VP, Gustavo Meirelles, highlights the company's leadership changes and its focus on enhancing product offerings [3] Company Focus - The company emphasizes a strong focus on physicians and their needs, indicating a commitment to understanding and addressing the medical community's requirements [2] - Presentations will cover innovations and products, showcasing the company's efforts to drive results and cash flow [3] Leadership and Structure - The introduction of Gustavo Meirelles as the new Medical VP signifies a strategic move to strengthen the executive board with medical expertise [3] - The event includes an institutional panel moderated by Virgilio Gibbon, indicating a structured approach to discussions and presentations [2]